As the second-quarter earnings season gets underway, these three healthcare stocks – including a biotech that now has a near monopoly on the cystic fibrosis space thanks to a rival’s stumble – are strong favorites of top analysts. CLICK HERE.
As the second-quarter earnings season gets underway, these three healthcare stocks – including a biotech that now has a near monopoly on the cystic fibrosis space thanks to a rival’s stumble – are strong favorites of top analysts. CLICK HERE.